Actinogen Medical - Executive interview
Actinogen Medical is an ASX-listed biotech developing its lead asset Xanamem, a specific 11β-HSD1 inhibitor designed to treat cognitive impairment...
811 Views
Actinogen Medical - Well-timed XanaHES study saves the day
Actinogen’s share price has experienced a rather volatile period since May 2019, when it decreased c 70% following the disappointing Phase II...
1.3k Views
Actinogen Releases Phase II Interim Result and Receives US Cornerstone Investment
Actinogen Medical Ltd (ACW AU) announced the results of the Interim Analysis of its Phase II XanADu trial that is conducted independently by the...
222 Views
New FDA Draft Rules Ease Approval for Alzheimer's Drugs
This short insight was written to demonstrate the importance of using biomarkers in clinical trials for Alzheimer's Disease (AD), and is intended...
228 Views
Will Actinogen Ace Alzheimer's?
Alzheimer’s disease is an incurable neurodegenerative disorder that robs the affected individuals of memory, self-care and quality of life,...
359 Views